- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Cystic Fibrosis
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Arginase Inhibitor
Cystic Fibrosis - Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Therapeutic Areas
Publications and Presentations
Check out our publications and poster presentations.
November 2021
A Phase 1b Randomized, Double-blind, Placebo-controlled, Dose Escalation Trial of CB-280, an Arginase Inhibitor, in Patients With Cystic FibrosisNorth American Cystic Fibrosis Conference
September 2021
KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2- Mutated Non-squamous Metastatic NSCLCWorld Conference on Lung Cancer
June 2021
CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib vs. Placebo + Cabozantinib in Patients With Advanced/Metastatic Renal Cell Carcinoma that Progressed on Immune Checkpoint Inhibitor or Anti-Angiogenic TherapiesAmerican Society of Clinical Oncology
January 2021
A Phase 1/2 Study of Safety and Efficacy of the Arginase Inhibitor INCB001158 Plus Chemotherapy in Patients With Advanced or Metastatic Biliary Tract CancersASCO Gastrointestinal Cancers Symposium
December 2020
AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim AnalysisAmerican Society of Hematology
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.